特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 普瑞眼科医院集团股份有限公司（以下简称"公司"）于近日收到国泰海 通证券股份有限公司（以下简称"国泰海通"）出具的《关于更换普瑞眼科医 院集团股份有限公司持续督导保荐代表人的函》。现将具体情况公告如下： 国泰海通作为公司首次公开发行股票并在创业板上市的保荐机构，原指派 李沁杭先生和田卓玲女士担任公司首次公开发行股票并在创业板上市项目保荐 代表人，负责保荐工作及持续督导工作，持续督导期已于2025年12月31日届满， 截至本公告披露日，公司募集资金尚未使用完毕，根据相关规定，国泰海通对 此未尽事项继续履行持续督导义务。 原保荐代表人田卓玲女士因工作安排变动，无法继续从事对公司的持续督 导工作。为保证持续督导工作的有序进行，国泰海通现委派保荐代表人叶盛荫 先生（简历详见附件）接替田卓玲女士担任公司持续督导工作的保荐代表人， 继续履行持续督导职责。 本次保荐代表人更换后，公司首次公开发行股票并在创业板上市项目的持 续督导保荐代表人为李沁杭先生和叶盛荫先生，持续督导期至中国证券监督管 理委员会和深圳证券交易所 ...

关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东股份解除质押的基本情况 证券代码：301239 证券简称：普瑞眼科 公告编号：2026-006 普瑞眼科医院集团股份有限公司（以下简称"公司"）近日接到控股股东 成都普瑞世纪投资有限责任公司（以下简称"普瑞投资"）的通知，获悉普瑞 投资将其所持有的公司部分股份办理了股票解除质押业务。具体事项如下： 普瑞眼科医院集团股份有限公司 | 股东 | 是否为控股股 东或第一大股 | 本次解除质 | 占其所 | 占公司 | 质押起 | 质押解 | 质权 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 押数量 | 持股份 | 总股本 | | | | | 名称 | 东及其一致行 | （股） | 比例 | 比例 | 始日 | 除日 | 人 | | | 动人 | | | | | | | | | | | | | | | 西藏 | | 普瑞 | 是 | 6,211,200 | 11.56% | 4.15% | 2025年3 | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东股份解除质押的基本情况 普瑞眼科医院集团股份有限公司（以下简称"公司"）近日接到控股股东 成都普瑞世纪投资有限责任公司（以下简称"普瑞投资"）的通知，获悉普瑞 投资将其所持有的公司部分股份办理了股票解除质押业务。具体事项如下： | 是否为控股股 | 本次解除质 | 占其所 | 占公司 | 股东 | 东或第一大股 | 质押起 | 质押解 | 质权 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 押数量 | 持股份 | 总股本 | 名称 | 东及其一致行 | 始日 | 除日 | 人 | （股） | 比例 | 比例 | | | 动人 | 成都 | | | | | | | | | | | | 中小 | 企业 | | | | | | | | | | | | 普瑞 | 2023年3 | 2026年3 | 融资 | 是 | 3,300,000 | 6.14% | 2.21% | 投资 | 月17日 | ...

普瑞眼科医院集团股份有限公司 证券代码：301239 证券简称：普瑞眼科 公告编号：2026-004 关于控股股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东股份质押及解除质押的基本情况 普瑞眼科医院集团股份有限公司（以下简称"公司"）近日接到控股股东 成都普瑞世纪投资有限责任公司（以下简称"普瑞投资"）的通知，获悉普瑞 投资将其所持有的公司部分股份办理了股票质押及解除质押业务。具体事项如 下： 1．本次股份质押基本情况 | 是否 | 为控 | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 是 | 股股 | 否 | 质 | | | | | | | | | | | | | | 东或 | 占公 | 质 | 占其所 | 是否 | 为 | 质押 | 押 | 股东 | 第一 | 本次质押数 | 司总 | 质权 | 押 | ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2026-003 普瑞眼科医院集团股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东股份质押的基本情况 普瑞眼科医院集团股份有限公司（以下简称"公司"）近日接到控股股东 成都普瑞世纪投资有限责任公司（以下简称"普瑞投资"）的通知，获悉普瑞 投资将其所持有的公司部分股份办理了股票质押业务。具体事项如下： | 是否 | 为控 | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 是 | 股股 | 否 | 质 | | | | | | | | | | | | | | | | 股 | 东或 | 质 | 本次质押 | 占其所 | 占公司 | 是否 | 为 | 质押 | 押 | 东 | 第一 | 质权 | 押 | | | | | | 数 ...

Core Viewpoint - The expansion of visa-free access in China has led to a significant increase in international medical tourism, particularly in Shanghai, which is becoming a preferred destination for foreign patients seeking advanced medical care [1][2]. Group 1: International Medical Tourism Growth - Shanghai has rich medical resources and has launched international medical pilot programs in both public and private hospitals since 2020, enhancing its global medical brand recognition [1]. - The implementation of the local standard for international medical services in Shanghai in 2024 is expected to further elevate the city's medical reputation internationally [1]. Group 2: Patient Experiences and Success Stories - Kevin, a Chinese doctor practicing in Canada, brought his daughter to Shanghai for a complex robotic pancreatic surgery, which was successful and preserved her spleen, showcasing the advanced medical capabilities in Shanghai [2][3]. - Zara, a Brazilian girl, underwent a significant reconstructive surgery at Shanghai Ninth People's Hospital, allowing her to walk independently and wear matching shoes for the first time, highlighting the hospital's expertise in complex cases [4]. Group 3: Specialized Medical Services - Shanghai hospitals are increasingly utilizing social media to connect with international patients, providing remote consultations and personalized treatment plans [2][6]. - The Shanghai Ninth People's Hospital has received patients from over 20 countries, demonstrating its international reach and the effectiveness of its medical services [3][6]. Group 4: Unique Offerings in Traditional Chinese Medicine - Shanghai's traditional Chinese medicine institutions are developing international departments to cater to foreign patients, offering unique experiences such as acupuncture and herbal treatments [5]. - The establishment of the international medical department at Shanghai University of Traditional Chinese Medicine aims to showcase the advantages of traditional medicine in chronic disease management and rehabilitation [5]. Group 5: Innovative Medical Practices - Shanghai hospitals are adopting a "technology + service" model to provide efficient and personalized care for international patients, including remote follow-ups and collaboration with overseas medical institutions [6]. - The Shanghai Ninth People's Hospital has established partnerships with 21 insurance companies to facilitate seamless payment processes for international patients, enhancing their overall experience [6]. Group 6: Private Hospital Developments - Private medical institutions in Shanghai, such as Baohui Medical, are carving out unique roles in the international medical landscape, serving patients from 77 countries and focusing on personalized care [7][8]. - Baohui Medical is implementing rapid diagnostic and treatment models to cater to the needs of international patients with tight schedules, optimizing their medical experience [8]. Group 7: Advanced Eye Care Services - Shanghai Puri Eye Hospital has attracted international patients seeking advanced cataract surgeries, with its leading experts recognized globally for their innovative techniques [9][10]. - The hospital aims to compete with public institutions by offering specialized services and advanced technology, contributing to the growth of Shanghai's international medical sector [10].

Core Viewpoint - The company, Puri Eye Hospital, forecasts a revenue of 2.75 billion to 2.85 billion yuan for 2025, with a net profit loss estimated between 50 million to 69 million yuan, indicating a reduction in losses compared to the previous year [1][2]. Group 1: Financial Performance - The expected revenue for 2025 is between 2.75 billion and 2.85 billion yuan, while the net profit loss is projected to be between 50 million and 69 million yuan, showing an improvement in loss compared to 2024 [2]. - The official annual report will provide detailed financial data and business explanations [2]. Group 2: Project Development - Since 2023, the company has been advancing its "national chain + local integration" expansion strategy, opening over ten new ophthalmology medical institutions that are currently in the market cultivation phase [3]. - The new facilities incur significant fixed asset depreciation and personnel costs, creating temporary pressure on overall profits [3]. - The potential for scale effects to further reduce losses as revenue gradually increases is a point of interest [3]. Group 3: Business and Technology Development - In 2025, Puri Eye Hospital will be among the first institutions in the country to introduce the new generation of Carl Zeiss all-laser SMILE Pro technology for refractive surgery [4]. - The company will also focus on promoting femtosecond laser-assisted cataract surgery and other high-end solutions to optimize the business structure of refractive and cataract projects, aiming to enhance the average transaction value [4]. Group 4: Industry Policy and Environment - The national bulk procurement policy for artificial crystalline lenses has been fully implemented in 2025, along with reforms in medical insurance payment methods, which structurally impact the revenue and profit margins of the company's cataract projects [5]. - The evolution of policy factors is expected to remain a focal point of industry attention [5]. Group 5: Shareholder Pledge - As of February 6, 2026, the total pledge ratio of the company is 18.35%, with a total of 27.4612 million shares pledged across 10 transactions, indicating stability in recent data [6].

Market Overview - On February 4, the medical services sector rose by 1.18% compared to the previous trading day, with Haitai Biological leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Medical Services Sector Performance - Haitai Biological (300683) closed at 32.72, up 8.56%, with a trading volume of 144,400 shares and a transaction value of 464 million [1] - MediX (688202) closed at 63.84, up 3.70%, with a trading volume of 46,200 shares and a transaction value of 289 million [1] - Other notable performers include: - Purui Eye Hospital (301239) at 35.56, up 2.92% [1] - Tigermed (300347) at 64.94, up 2.75% [1] - Kanglong Chemical (300759) at 30.37, up 2.57% [1] Capital Flow Analysis - The medical services sector saw a net inflow of 427 million from institutional investors, while retail investors experienced a net outflow of 439 million [2][3] - Notable net inflows from institutional investors include: - Tigermed (300347) with 158 million [3] - Aier Eye Hospital (300015) with 118 million [3] - WuXi AppTec (603259) with 112 million [3] Individual Stock Capital Flow - Tigermed (300347) had a net institutional inflow of 158 million, accounting for 14.54% of its trading volume [3] - Aier Eye Hospital (300015) had a net institutional inflow of 118 million, representing 12.46% of its trading volume [3] - Other stocks with significant institutional inflows include: - WuXi AppTec (603259) with 112 million [3] - Kanglong Chemical (300759) with 58.6 million [3]

Financial Performance - The company expects a net profit of -69 million CNY for the year 2025, compared to -50 million CNY in the same period last year[5] - Revenue is projected to be 2.75 billion CNY, slightly down from 2.85 billion CNY in the previous year, but an increase from 2.68 billion CNY two years ago[5] Market Competition - The company faces intensified competition in the ophthalmology market, impacting gross margins despite an increase in business volume and revenue in core areas[7] Policy Impact - The implementation of national policies for bulk procurement of artificial lenses continues to structurally affect revenue and profit margins in the cataract project[7] - The company is focusing on promoting advanced cataract surgeries to counteract the impact of price reductions due to policy changes[9] Strategic Expansion - The company is undergoing a strategic expansion with significant fixed costs, including depreciation and personnel expenses, which are currently pressuring overall profits[8] Technological Advancements - The introduction of new technologies, such as the Carl Zeiss SMILE Pro, has enhanced the average transaction value and driven revenue growth in refractive surgery[9] Investment Assessment - The acquisition of Dongguan Guangming Eye Hospital has led to a slowdown in revenue and profit growth, prompting the company to assess goodwill impairment for this investment[9]

Group 1 - The core viewpoint of the news is that Puri Eye Hospital has shown a slight increase in stock price and has low financing and margin trading balances, indicating a cautious market sentiment towards the company [1] - On January 26, Puri Eye Hospital's stock rose by 0.66%, with a trading volume of 66.66 million yuan. The financing buy amount was 6.065 million yuan, while the financing repayment was 7.893 million yuan, resulting in a net financing outflow of 1.828 million yuan [1] - As of January 26, the total financing and margin trading balance for Puri Eye Hospital was 70.3743 million yuan, with the financing balance accounting for 1.33% of the circulating market value, which is below the 10th percentile level over the past year [1] Group 2 - As of September 30, Puri Eye Hospital had 10,400 shareholders, a decrease of 1.98% from the previous period, while the average circulating shares per person increased by 104.71% to 13,608 shares [2] - For the period from January to September 2025, Puri Eye Hospital achieved an operating income of 2.201 billion yuan, representing a year-on-year growth of 2.99%, and a net profit attributable to shareholders of 16.3491 million yuan, up 3.21% year-on-year [2] - Since its A-share listing, Puri Eye Hospital has distributed a total of 74.5074 million yuan in dividends [3]